Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Reporting of transactions with ALK-Abelló A/S' B-shares and associated securities by person closely associated with person discharging managerial responsibly

Posted on: 11 Dec 17

Copenhagen, 2017-12-11 16:29 CET (GLOBE NEWSWIRE) --  

With reference to company announcement no. 35/2017 and no. 36/2017 regarding offering, pricing and completing of the offering of new shares in ALK-Abelló A/S, company registration no. (CVR) 63 71 79 16 ("ALK"), ALK hereby, pursuant to the Market Abuse Regulation article 19, notifies information of the following transaction made by Lundbeckfond Invest A/S who is closely associated with persons discharging managerial responsibilities with ALK. 

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) reports the following transactions: 

1. Details of the Reporting Person / Closely Associated Person
a) Name Lundbeckfond Invest A/S
2. Reason for the notification
a) Position/status Closely associated with board member, Lene Skole
b) Initial notification/amendment Initial notification
3. Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name ALK-Abelló A/S
b) LEI code 529900SGCREUZCZ7P020
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of trans-action; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instru-ment AA-shares and B-shares
DK0060027142 (B-shares)
b) Nature of the transaction Subscription of new AA- shares and B-shares
c) Price(s) and volume(s) Price(s) Volume(s)
  AA-shares DKK 63,529,680 92,072
  B-shares DKK 217,965,480 315,892
d) Aggregated information and aggregated volume price 407,964 shares
DKK 281,495,160
e) Date of transaction 2017-12-11
f) Place of the transaction NASDAQ Copenhagen


ALK-Abelló A/S

For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525


Last updated on: 11/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.